Eli Lilly and Company (LLY)
| Market Cap | 676.67B |
| Revenue (ttm) | 49.00B |
| Net Income (ttm) | 11.11B |
| Shares Out | 897.74M |
| EPS (ttm) | 12.29 |
| PE Ratio | 61.33 |
| Forward PE | 30.26 |
| Dividend | $6.00 (0.80%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 7,273,751 |
| Open | 727.87 |
| Previous Close | 734.57 |
| Day's Range | 722.18 - 765.33 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 1,005.05 (+33.34%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,005.05, which is an increase of 33.34% from the latest price.
News
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Drugmakers are spared worst-case drug pricing scenario for now
Executive order says if companies and the government don't align on tying U.S. drug prices to other countries, the administration will impose its own plan.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up t...
Trump says executive order will slash the cost of prescription drugs
President Donald Trump signed an executive order targeting the cost of prescription drugs. Prices will be cut by as much as 80%, and some immediately, he said at a press conference.
20 stocks of companies showing excellent earnings-season trends even as the economy cools
With U.S. economic growth turning negative during the first quarter, this earnings season's results might shed some light on which companies may best weather the disruption brought about by President ...
Trump Announces Executive Order to Lower Drug Prices
President Donald Trump says he'll sign an executive order that will lower drug prices for Americans. The order aims to align patient costs with lower prices paid abroad, focusing on Medicare and weigh...
White House release details on executive order on drug prices: Here's what to know
CNBC's Eamon Javers reports on the latest news.
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival's Wegovy
The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs.
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.
Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine
Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist circ...
Wellness companies eager to avoid WeightWatchers' fate embrace weight-loss drugs
Health and wellness companies are embracing weight-loss drugs and building offerings around them in an effort to avoid the fate of WeightWatchers, which declared bankruptcy this week, citing vastly in...
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
INDIANAPOLIS and WEST LAFAYETTE, Ind. , May 9, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, wit...
Pressure is still on the pharma sector, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
Top Stock Movers Now: AB InBev, Molson Coors, Eli Lilly, and More
U.S. equities advanced at midday as President Donald Trump announced a new trade deal with the United Kingdom. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.
Lilly announces transitions in executive leadership
INDIANAPOLIS , May 8, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced executive leadership transitions that will further enhance the company's ability to drive sustained, long-t...
US judge sides with FDA's removal of Lilly's weight loss drug from shortage list
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly's blockbuster weight loss and diabetes drugs Zepbound and Mounjaro off a list of medicines in short supply, ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
Pharma sector still investable, faces added headwinds, says BMO's Siegerman
Evan Siegerman, BMO Capital Markets, joins 'Fast Money' to talk new headwinds facing the pharma sector.
Trump Sets Pharma Tariffs Deadline. The Fallout for Eli Lilly, Pfizer, Other Drugmakers.
The president signed an executive order to promote domestic pharma production Monday, and said that news on drug tariffs will come within two weeks.
Trump signs order to boost domestic drug manufacturing as pharma tariff threat looms
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
Lilly declares second-quarter 2025 dividend
INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common st...
Top 50 High-Quality Dividend Stocks For May 2025
I track 50 high-quality dividend growth stocks to identify opportune investments, updating valuation ratings daily to focus on attractive opportunities. Despite a market sell-off, my investable univer...
Eli Lilly's Meltdown Triggers Near Doubling Upside Potential - Reiterate Buy
LLY's valuation remains highly attractive post-market overreaction, with the FY2025 bottom-line impact merely attributed to one-time acquired IPR&D expenses from ongoing M&A activities. Despite the ta...